Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study

Clarence Yen\textsuperscript{a}  Rohini Sharma\textsuperscript{a}  Lorenza Rimassa\textsuperscript{b}  Tadaaki Arizumi\textsuperscript{c}  Dominik Bettinger\textsuperscript{d,e}  Huay Yee Choo\textsuperscript{a}  Tiziana Pressiani\textsuperscript{b}  Michela E. Burlone\textsuperscript{f}  Mario Pirisi\textsuperscript{f}  Laura Giordano\textsuperscript{b}  Anisa Abdulrahman\textsuperscript{a}  Masatoshi Kudo\textsuperscript{c}  Robert Thimme\textsuperscript{d,e}  Joong Won Park\textsuperscript{g}  David James Pinato\textsuperscript{a}

\textsuperscript{a}Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; \textsuperscript{b}Medical Oncology and Haematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, Italy; \textsuperscript{c}Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan; \textsuperscript{d}Department of Medicine II, University Medical Center, and \textsuperscript{e}Berta Ottenstein Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany; \textsuperscript{f}Department of Translational Medicine, Università degli Studi del Piemonte Orientale “A. Avogadro,” Novara, Italy; \textsuperscript{g}Center for Liver Cancer, National Cancer Center Hospital, Goyang, South Korea

Keywords
Hepatocellular carcinoma · Sorafenib · Treatment stage migration · Prognosis · Treatment-naïve patients

Abstract
Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease. Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival. Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment naïve (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization \( (n = 413; 79\%) \). The primary endpoint was overall survival (OS) from sorafenib initiation with prognostic factors tested on uni- and multivariate analyses. Results: Median OS for the entire cohort was 9 months; the median sorafenib duration was 2.8 months, with discontinuation being secondary to progression \( (n = \) \text{...})
PT patients had significantly longer OS than TN patients (10.5 vs. 6.6 months; \( p < 0.001 \)). Compared to TN patients, PT patients had a better Child-Pugh (CP) class (CP A: 57 vs. 47%; \( p < 0.001 \)) and a lower BCLC stage (BCLC A–B, 40 vs. 30%; \( p = 0.007 \)). PT status preserved an independent prognostic role (\( p = 0.002 \)) following adjustment for BCLC stage, \( \alpha \)-fetoprotein, CP class, aetiology, and post-sorafenib treatment status. PT patients were more likely to receive further anticancer treatment after sorafenib (31 vs. 9%; \( p < 0.001 \)). **Conclusion:** Patients receiving sorafenib after having failed curative or locoregional therapies survive longer and are more likely to receive further treatment after sorafenib. This suggests an incremental benefit to OS from sequential exposure to multiple lines of therapy, justifying treatment stage migration in eligible patients.

**Introduction**

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide at a mortality-to-incidence ratio of 0.95 [1, 2] and 5-year survival rates ranging from 5 to 20% [3]. Treatment options for HCC have widened and improved over time to include surgical, locoregional, and systemic therapies [4], and staging algorithms including the Barcelona Clinical Liver Cancer (BCLC) system have facilitated a rational treatment allocation process. Despite increasing efforts addressed at harmonizing management decisions, there is recognized geographical variation in the provision of radical and palliative treatments in HCC where regional preferences and the availability of each treatment modality among the treating multidisciplinary tumour board affect outcomes [5, 6].

The last decade has seen sorafenib emerging as the first systemic agent to produce a survival benefit of approximately 3 months in the treatment of advanced HCC [7, 8]. The magnitude of the survival benefit documented in pre-registration trials is extrapolated from a population of patients with advanced HCC, Child-Pugh (CP) class A, for whom sorafenib represented the first-line option for systemic therapy [9].

In clinical practice, the provision of sorafenib is not solely restricted to treatment-naïve (TN) patients who present with advanced HCC and preserved liver function, but also extends to patients who have progressed after curative or locoregional therapies. The provision of sorafenib as the next most suitable therapy in the context of disease progression or patient ineligibility to further locoregional therapies, a concept also termed “treatment stage migration” [10], is globally the most common indication for the use of sorafenib, as shown in the GIDEON study, where 57% of the patients on sorafenib had previously received local surgical ablative therapy or transarterial chemoembolization (TACE) [11]. Subanalyses of pre-registration trials have initially demonstrated that sorafenib treatment leads to a significant survival advantage over placebo in patients with HCC irrespective of a number of key clinicopathologic features, including disease aetiology, baseline tumour burden, performance status, tumour stage, and prior therapy [12, 13]. However, it is unclear whether TN patients have a life expectancy similar to that of patients who are migrated to sorafenib after failure of radical/locoregional therapies in routine clinical care, where provision of sorafenib does not strictly follow clinical trial eligibility criteria and often extends to subjects with a wider range of liver functional reserve and BCLC stage, variables that are likely to make the expected survival benefit from sorafenib dissimilar to that reported in phase III trial data [14, 15]. Moreover, since the treatment landscape of HCC has recently expanded to include second-line therapies [16, 17], it is important to understand whether treatment sequencing prior to sorafenib might influence the eligibility of patients to receive further systemic treatment lines following sorafenib discontinuation [18].
To address these issues, we designed this study aiming to compare and contrast the clinicopathologic features and survival outcomes of patients who received sorafenib for two different clinical indications: (1) as first-line therapy for previously untreated HCC (TN group) or (2) in the context of disease progression or relapse following prior treatment with radical or locoregional therapies (PT group).

**Methods**

This observational study was conducted on a prospectively maintained, multicentre data set of 867 consecutive patients receiving sorafenib from 6 tertiary referral centres with HCC multidisciplinary services between 2008 and 2016. From this database, 77 patients who had previously received systemic therapy and 5 CP class C patients were excluded.

The final data set of 785 patients consisted of 449 patients (61.0%) from Europe and 306 (39.0%) from Asia. The European centres included 95 patients (12.1%) from Imperial College London (UK), 68 patients (8.7%) from University Hospital Freiburg (Germany), 53 patients (6.8%) from the Academic Liver Unit in Novara (Italy), and 263 patients (33.5%) from the Humanitas Cancer Center in Milan (Italy). The Asian subgroup included 192 patients (24.5%) from Kindai University, Osaka (Japan), and 114 patients (14.5%) from the National Cancer Center Hospital, Goyang (South Korea) (Fig. 1). All patients met the criteria for a histological and/or radiological diagnosis of HCC [10].

Sorafenib was administered after multidisciplinary discussion, either as the first anticancer therapy or in the setting of relapse, failure, or ineligibility to radical or locoregional treatments. The clinical follow-up of the patients during sorafenib treatment included routine blood tests, physical examination, and adverse event assessment before each cycle of sorafenib. Radiologic staging was performed using computerized
tomography and/or magnetic resonance imaging, as clinically indicated. The patients were re-assessed radiologically for disease response status every 8–12 weeks using the modified RECIST (mRECIST) criteria on contrast-enhanced imaging.

The patients’ clinicopathological characteristics, including treatments received prior to and after sorafenib, were collected, and the baseline CP class and BCLC stage were reconstructed [19, 20]. The primary endpoint of this study was overall survival (OS), calculated from the date of sorafenib commencement until death or last follow-up. In addition, we performed a subgroup analysis on post-sorafenib treatment status to explore its confounding effect on survival in the PT and TN groups.

The study was performed following research ethics committee approval from all participating institutions in accordance with the good clinical practice standards published in the Declaration of Helsinki.

| Table 1. Clinicopathologic features at study baseline |
|---------------------------------------------|
| Patient characteristic              | Treatment naïve n = 264 | Prior treatment n = 521 | p value |
| Median age at sorafenib initiation (range), years | 68.6 (59.9–76.2) | 69.5 (61.4–76.6) | 0.309 |
| Gender | Male | Female | Male | Female | 0.135 |
| | 204 (77.3%) | 60 (22.7%) | 426 (81.8%) | 95 (18.2%) |
| Aetiology | | | | | 0.003 |
| Hepatitis B virus | 58 (22.0%) | 125 (24.0%) |
| Hepatitis C virus | 76 (28.8%) | 203 (39.0%) |
| Non-viral | 130 (49.2%) | 193 (37.0%) |
| Geography | | | | | <0.001 |
| Western | 197 (74.6%) | 282 (54.1%) |
| Eastern | 67 (25.4%) | 239 (45.9%) |
| Extrahepatic spread | | | | | 0.619 |
| Absent | 162 (63.3%) | 317 (61.4%) |
| Present | 94 (36.7%) | 199 (38.6%) |
| Portal vein invasion | | | | | <0.001 |
| Absent | 170 (64.4%) | 397 (76.2%) |
| Present | 94 (35.6%) | 124 (23.8%) |
| α-Fetoprotein | | | | | 0.004 |
| >400 ng/mL | 121 (46.9%) | 181 (36.0%) |
| <400 ng/mL | 137 (53.1%) | 322 (64.0%) |
| Child-Pugh class | | | | | 0.009 |
| A | 117 (47.2%) | 283 (57.3%) |
| B | 131 (52.8%) | 211 (42.7%) |
| BCLC stage | | | | | 0.007 |
| A/B | 80 (30.3%) | 209 (40.1%) |
| C | 184 (69.7%) | 312 (59.9%) |
| Median duration of sorafenib treatment (range), months | 2.9 (1.6–6.9) | 2.6 (1.4–6.9) | 0.755 |
| Previous treatment | | | | | |
| Liver resection | – | 148 (28.4%) | – |
| Liver transplant | – | 7 (1.3%) | – |
| RFA | – | 168 (32.2%) | – |
| TACE | – | 413 (79.3%) | – |

Bold type denotes significance. BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.
Statistical Analysis

The patients’ characteristics were analysed by descriptive statistical methods and are presented as means or medians, as appropriate. Normality was tested with the Shapiro-Wilk test. The Pearson χ² test or Fisher exact test was used for analysis of proportions, as appropriate. Kaplan-Meier curves with log-rank testing were used to perform a univariate survival analysis, with significant factors (p < 0.05) being entered into Cox regression models. All statistical analyses were performed using SPSS version 21.0 (IBM Inc., Chicago, IL, USA) and conducted at 95% confidence intervals (95% CI), with a two-tailed level of significance at p < 0.05.

Results

Patient Characteristics

A total of 785 patients receiving sorafenib for HCC were included: 521 patients (66.4%) had been pre-treated with either potentially curative or locoregional treatment (PT group) and 264 patients (33.6%) were treatment naïve (TN group). The treatment modalities in the PT group included TACE (n = 413; 79.3%), radiofrequency ablation (RFA; n = 168; 32.2%), and liver resection (n = 148; 28.4%). The mean number of prior treatment lines was 2, with 282 patients (54.1%) having received only 1 prior line of treatment.

The differential distribution of the clinical characteristics of the TN and PT patients is presented in Table 1. There were no differences in age at sorafenib initiation, gender distribution, and extrahepatic spread between the TN and PT cohorts at baseline. The treatment duration was similar across the groups: 2.9 months (95% CI: 1.6–6.9) in the TN group and 2.6 months (95% CI: 1.4–6.9) in the PT group (p = 0.75). Sorafenib discontinuation primarily followed progression of disease (n = 454; 58.1%) and unacceptable toxicity (n = 149; 19.0%). Hepatitis C virus (HCV) aetiology was more prevalent in PT than in TN patients (n = 203, 39.0%, vs. n = 76, 28.8%; p = 0.003). There were more patients treated in Western centres in the TN group (n = 197; 74.6%) than in the PT group (n = 282; 54.1%) (p < 0.001). At baseline, 312 patients (59.9%) in the PT group satisfied BCLC stage C criteria, as compared to 184 patients (69.7%) in the TN group (p = 0.007). The PT group had a higher proportion of CP class A patients (n = 283; 57.3%) than the TN group (n = 117; 47.2%) (p = 0.009), as well as lower α-fetoprotein (AFP) levels, with 181 patients (36.0%) having an AFP level >400 ng/mL in the PT group as compared to 121 patients (46.9%; p = 0.004) in the TN group. There were no differences in dose reductions between the two groups (n = 99, 38.2%, in the TN group and n = 170, 33.0%, in the PT group; p = 0.151).

Prognostic Relationship between Prior Treatment Status and Sorafenib-Specific Survival in Patients with HCC

Overall, 637 patients (81.1%) had died by the time of analysis, 233 (88.3%) in the TN group and 404 (77.5%) in the PT group. Median OS across the whole study population was 9.0 months (95% CI: 8.2–9.7). The patients in the Eastern centres had a median OS of 8.5 months (n = 306; 95% CI: 7.1–9.9 months), while the patients in the Western centres had a non-dissimilar median OS of 9.9 (n = 479; 95% CI: 8.2–10.0 months: log-rank p = 0.074). On univariate analysis, the patients in the PT cohort had a significantly longer median OS of 10.5 months (95% CI: 9.2–11.8), compared to 6.6 months (95% CI: 5.6–7.6; log-rank p < 0.001) in the TN group (Fig. 2a). Other univariate predictors of poorer OS included aetiology of chronic liver disease (p = 0.006), AFP >400 ng/mL (p < 0.001), portal vein invasion (PVI; p < 0.001), extrahepatic spread (p < 0.001), CP class (p = 0.016), and BCLC stage (p < 0.001), as shown in Table 2 and Figure 2. The multivariate analyses revealed prior treatment status to remain an independent predictor of OS (HR 1.32; 95% CI: 1.10–1.57; p = 0.002) following adjustment.
Fig. 2. Kaplan-Meier curves describing the overall survival of patients with hepatocellular carcinoma treated with sorafenib according to prior treatment status (pre-treated or treatment naïve) (a), BCLC stage (b), and etiology of the underlying cirrhosis (c). BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus.
for aetiology, CP class, BCLC stage, and AFP level (Table 2). When stratified according to BCLC stage, the prior treatment status was able to identify patient subsets with clinically meaningful differences in survival, ranging from 18.6 months for PT BCLC stage A/B patients to 8 months for TN BCLC stage A/B patients who were unfit to receive radical or locoregional therapies (online suppl. Table 1; see www.karger.com/doi/10.1159/000480441 for all online suppl. material).

We evaluated the relationship between prior treatment status and best type of radiologic response according to the mRECIST criteria. Radiologically proven disease progression was documented in 58 TN patients (63.7%) and 162 PT patients (59.3%), with no difference in response rate between the groups ($p = 0.22$) (Table 3).

In the analysis of treatment after sorafenib discontinuation, we excluded patients on ongoing sorafenib ($n = 23$) or in disease remission ($n = 7$). In the entire study cohort, provision of further anticancer treatment ($n = 119; 24.2\%$) was associated with an improved median OS of 18.3 months (95% CI: 13.8–22.9), as compared to 5.8 months (95% CI: 5.0–6.6) among

### Table 2. Univariate and multivariate analyses of survival

|                        | n   | Univariate | Multivariate |
|------------------------|-----|------------|--------------|
|                        |     | OS, months | 95% CI       | p value | HR  | 95% CI | p value |
| Gender                 |     |            |              |         |     |        |         |
| Male                   | 630 | 9.0        | 8.1–9.8      | 0.292   | –   | –      | –       |
| Female                 | 155 | 9.2        | 7.2–11.2     | –       | –   | –      | –       |
| Aetiology              |     |            |              |         |     |        |         |
| Non-viral              | 323 | 8.7        | 7.8–9.6      | **0.006** | –   | –      | 0.103   |
| Hepatitis B virus      | 183 | 6.8        | 5.4–8.2      | 1.04    | 0.83| 1.29   |         |
| Hepatitis C virus      | 279 | 11.3       | 9.4–13.2     | 0.84    | 0.69| 1.01   |         |
| Geography              |     |            |              | **0.074** | –   | –      | –       |
| Western                | 479 | 9.1        | 8.2–10.0     | –       | –   | –      | –       |
| Eastern                | 306 | 8.5        | 7.1–9.9      | –       | –   | –      | –       |
| α-Fetoprotein          |     |            |              |         |     |        |         |
| >400 ng/mL             | 459 | 11.8       | 10.2–13.3    | **<0.001** | –   | –      | **<0.001** |
| <400 ng/mL             | 302 | 5.6        | 4.7–6.6      | 1.82    | 1.53| 2.16   |         |
| Portal vein invasion   |     |            |              |         |     |        |         |
| Absent                 | 567 | 9.9        | 8.8–11.1     | **<0.001** | –   | –      | –       |
| Present                | 218 | 5.9        | 4.7–7.0      | –       | –   | –      | –       |
| Extrahepatic spread    |     |            |              |         |     |        |         |
| Absent                 | 479 | 9.7        | 8.6–10.8     | **<0.001** | –   | –      | –       |
| Present                | 293 | 7.0        | 5.7–8.3      | –       | –   | –      | –       |
| Child-Pugh class       |     |            |              |         |     |        |         |
| A                      | 400 | 9.2        | 7.9–10.5     | **0.016** | –   | –      | **0.046** |
| B                      | 342 | 8.6        | 7.6–9.6      | 1.19    | 1.00| 1.41   |         |
| BCLC stage             |     |            |              |         |     |        |         |
| A/B                    | 289 | 12.7       | 10.3–15.2    | **<0.001** | –   | –      | **<0.001** |
| C                      | 496 | 7.0        | 6.1–7.9      | 1.65    | 1.38| 1.98   |         |
| Treatment group        |     |            |              |         |     |        |         |
| Pre-treated            | 521 | 10.5       | 9.2–11.8     | **<0.001** | –   | –      | **0.002** |
| Treatment naïve        | 264 | 6.6        | 5.6–7.6      | 1.32    | 1.10| 1.57   |         |

Bold type denotes significance. OS, overall survival; BCLC, Barcelona Clinic Liver Cancer.
the patients who received best supportive care (BSC; \( n = 373; 75.8\% \); \( p < 0.001 \)), with an HR of 1.8 (95% CI: 1.4–2.2). In the patient cohort receiving further anticancer therapy, 64 patients (53.8%) received further systemic therapy, while 76 (63.9%) of them received locoregional therapy (hepatic arterial infusion chemotherapy or radioembolization), with 21 (17.6%) receiving both locoregional and systemic therapy after sorafenib. Upon sorafenib discontinuation, the patients in the PT group were more likely to receive further anticancer treatment (\( n = 105; 30.7\% \)) than the TN patients (\( n = 14; 9.3\% \); \( p < 0.001 \); Table 3).

Lastly, we address the potential confounding effect of post-sorafenib therapy status on OS. Among the patients who received BSC after sorafenib discontinuation, the PT group (\( n = 237; 63.5\% \)) had a longer median OS of 7.0 months (95% CI: 5.2–8.9), as compared to the TN group (\( n = 136; 36.5\% \)) with a median OS of 4.9 months (95% CI: 4.2–5.6; \( p = 0.007 \)), with an HR of 1.4 (95% CI: 1.1–1.7) (Fig. 3a). Similarly, among the patients who received further anticancer treatment after sorafenib, the PT group (\( n = 105; 88.2\% \)) had a longer median OS of 18.6 months (95% CI: 16.5–20.8), as compared to 7.0 months (95% CI: 6.5–7.6) in the TN group (\( n = 14; 11.8\% \); \( p = 0.004 \); Fig. 3b), with an HR of 2.3 (95% CI: 1.3–4.2). This confirmed that the prognostic stratification imparted by pre-sorafenib treatment status was maintained independently from post-sorafenib treatment.

**Discussion**

The multi-targeted tyrosine kinase inhibitor sorafenib has remained the only evidence-based systemic treatment option for patients with HCC for a decade, having been the first compound to demonstrate a significant survival benefit over placebo in two landmark phase III studies [7, 8]. Whilst the positioning of this treatment has initially coincided with the BCLC stage C category of patients (i.e., patients with metastases or PVI, a performance status of 0–2, and preserved liver function), the administration of sorafenib has progressively widened to include patients with earlier-stage disease who have progressed or are deemed ineligible to further radical or locoregional therapies.

These indications, defined within the BCLC guidelines as “treatment stage migration” [10], are based on subgroup analyses of clinical trials showing that sorafenib is more efficacious than placebo in advanced HCC irrespective of prior treatment [12, 13]. In the post-sorafenib era, however, inconclusive evidence exists to demonstrate whether PT and TN patient subpopulations might have a different life expectancy whilst on sorafenib treatment.
In addition, expanding level I evidence across the various stages of HCC has importantly shown that the efficacy of sorafenib is strongly dependent on the stage of the disease. The STORM trial has in fact revealed that sorafenib is ineffective in reducing the risk of relapse after resection or RFA in early-stage HCC\(^\text{[25]}\). Similarly, the SPACE trial and, subsequently, the TACE-2 trial have provided unequivocal evidence that the provision of sorafenib alongside TACE does not improve the survival of patients with intermediate-stage HCC\(^\text{[26–28]}\). Taken together, the evidence produced to date suggests significant heterogeneity in the clinical activity of sorafenib across stages and indications.

With this in mind, we conducted this study to evaluate whether the survival outcomes of patients receiving sorafenib as first-line anticancer therapy are significantly different from those of patients who are “migrated” to sorafenib after failure of prior radical or locoregional therapies. In our large, consecutive patient series, consisting of a multicentre database from

---

**Fig. 3.** Kaplan-Meier curves describing the differences in overall survival of patients classified according to prior treatment status following stratification by the type of therapy received after permanent sorafenib cessation: best supportive care (BSC) (a) or further active anticancer therapies (b).
6 tertiary referral centres across Europe and Asia, we confirmed that sorafenib-specific OS is significantly influenced by the previous anticancer treatment status.

In our study, the patients in the PT group had better liver functional reserve, lower tumour stages, higher AFP levels, and a lower prevalence of PVI, suggesting that the difference in survival observed between the pre-treatment and the treatment-naïve group may be attributed to differences in common clinicopathologic features of the disease [12, 20, 29–33]. However, when we performed multivariate analyses of survival, we found that the 4-month increase in the probability of survival associated with prior treatment was independent of liver functional reserve, stage, aetiology, and AFP levels, which is to suggest that the imbalance of prognostic factors may not entirely explain the difference in survival we observed between the groups.

Our results suggest that patients considered for sorafenib in the context of relapsed/progressive HCC after radical/locoregional therapies are clinically diverse from those who present with de novo metastatic disease – who, in our study, had shorter OS times despite an equal duration of sorafenib treatment and comparable radiologic responses. We cannot discount the possibility that biologic factors intrinsic to the molecular makeup of HCC might be at the basis of the different survival periods observed between the PT and the TN group, more so in light of recent evidence suggesting genomic diversity in the evolution of HCC [34]. It is possible that in the PT group, the HCC might have had a more indolent course that allowed early detection and facilitated the provision of multiple lines of treatment, leading to better patient selection. On the other hand, the diverse distribution of aetiologic factors across groups might be an equally important factor to underpin such biologic heterogeneity. Interestingly, in our study, we found the PT group to comprise more HCV-related cirrhotics, whose survival was significantly superior to those with other aetiologies, echoing evidence from recently published meta-analyses highlighting improved survival among patients with HCV-associated HCC treated with sorafenib [35].

Regardless of the causality, the diversity in prognostic outlook that we document here is a finding of greater consequence with the advent of second-line therapies for HCC. In our study, PT patients were less likely to receive BSC following sorafenib cessation, making this group an optimally suited patient population for further anticancer treatment upon permanent sorafenib cessation.

Our results may also have important implications for optimizing the sequencing of treatments for patients with HCC. Whilst limited by a non-randomized observational study design, our findings suggest that in patients who are initially eligible to radical/locoregional therapies, these should be prioritized over systemic treatment. The use of sorafenib as “salvage” treatment in the context of disease progression or relapse after radical/locoregional therapies does not seem to negatively affect outcome, being conversely associated with an improved survival probability despite the longer time from the original diagnosis of HCC that characterizes the PT group.

We acknowledge a number of limitations to our observations. Firstly, the multicentre observational nature of this study, whilst limiting systematic bias, is influenced by the heterogeneity in the provision of treatments prior to and after sorafenib therapy, with implications for the estimation of survival. Secondly, we could not adjust our analyses for the type or number of TACE procedures, a treatment strategy characterized by wide interinstitutional variability. Despite the acknowledged limitations, our patient data set is fully representative of the population of patients eligible to sorafenib [7, 8, 36]: the median OS of 10.4 months in our PT group is similar to that of the patients treated with TACE in the SHARP trial (median OS: 11.9 months) and with TACE or RFA in the Asian-Pacific trial (median OS: 7.3 and 10.5 months, respectively) [12, 13].
To conclude, in this observational study we have shown that TN patients receiving sorafenib as first-line anticancer therapy have profoundly different survival outcomes from those who received it after prior treatment for HCC. We have highlighted the sources of clinical heterogeneity, including stage and liver functional imbalance, underlying this difference. Indirectly, our study supports the provision of sorafenib in the context of treatment migration following failure of radical or locoregional therapies, and highlights that this patient population is optimally suited for second-line therapies. Whilst we could not control for potential confounders – including a different underlying biology, varying burden of disease within each BCLC stage, and a different and heterogeneity in the criteria for conversion from radical/locoregional to sorafenib – taken together, our study suggests that TN and PT patients should be regarded as different clinical entities, a finding that should be carefully weighted in clinical study design as well as in clinical practice.

Acknowledgements

D.B. is supported by the Berta Ottenstein Programme, Faculty of Medicine, University of Freiburg. D.J.P. is supported by the National Institute for Health Research (NIHR).

Disclosure Statement

The authors have no conflicts of interest to disclose.

Funding Sources

No specific funding was obtained to support the conduction of this study.

Author Contributions

Study concept and design: D.J.P., C.Y.; acquisition of data: D.J.P. and T.A., D.B., H.Y.C., L.R., M.E.B., T.P., M.P., L.G., A.A., M.K., R.T., J.W.P., and R.S.; analysis and interpretation of data: D.J.P., R.S., L.R., and C.Y.; drafting of the manuscript: C.Y. and D.J.P.; critical revision of the manuscript for important intellectual content: all the authors; statistical analysis: C.Y. and D.J.P.; administrative, technical, or material support: R.S., L.R., J.W.P., R.T., M.K., and M.P.; study supervision: D.J.P.

References

1 Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
3 American Cancer Society: Global Cancer Facts and Figures, ed 3. Atlanta, American Cancer Society, 2015.
4 Dhir M, Melin AA, Douaiher J, et al: A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–1125.
5 Leoni S, Piscaglia F, Serio I, et al: Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis 2014;46:549–555.
6 Park JW, Chen M, Colombo M, et al: Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155–2166.
7 Cheng A-L, Kang Y-K, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
8 Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
